Marinus (NASDAQ: MRNS) Names Michael R. Dougherty to Board, Prepares to Initiate Phase 2 Studies of Ganaxolone
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), on February 1, 2017, named Michael R. Dougherty to its board. A biopharmaceutical company, Marinus…